Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: A meta-analysis

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 24, Issue 10, 2014, Pages 1067-1073

  Chang, Y H ^a   Lin, K D ^b,c   Shin, S J ^c   Lee, Y J ^a  

^a Lee's Endocrinologic Clinic   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Atorvastatin; Diabetes mellitus; High density lipoprotein cholesterol; Meta analysis; Simvastatin; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE; TRIACYLGLYCEROL;

ARTICLE; ASIAN; COMORBIDITY; ETHNICITY; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; BLOOD; DIABETES MELLITUS, TYPE 2;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; SIMVASTATIN; TRIGLYCERIDES;

EID: 84908498432     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.04.010     Document Type: Article

References (30)

1. Chapman M.J. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. Cardiovasc Drugs Ther 2005, 19:135-139.
2. Tenenbaum A., Fisman E.Z., Motro M., Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006, 5:20.
3. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
4. Stevens R.J., Kothari V., Adler A.I., Stratton I.M. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001, 101:671-679.
5. Kothari V., Stevens R.J., Adler A.I., Stratton I.M., Manley S.E., Neil H.A., et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002, 33:1776-1781.
6. Sacks F.M., Tonkin A.M., Shepherd J., Braunwald E., Cobbe S., Hawkins C.M., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000, 102:1893-1900.
7. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. G. Heart Protection Study Collaborative.
8. Barter P., Gotto A.M., Larosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
9. Chang Y.H., Chang D.M., Lin K.C., Hsieh C.H., Lee Y.J. High-density lipoprotein cholesterol and the risk of nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2013, 23:751-757.
10. Sever P.S., Poulter N.R., Dahlof B., Wedel H., Collins R., Beevers G., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005, 28:1151-1157.
11. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
12. Chang Y.H., Lin K.C., Chang D.M., Hsieh C.H., Lee Y.J. Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in chinese type 2 diabetic patients. Rev Diabet Stud 2013, 10:213-222.
13. Liao J.K. Safety and efficacy of statins in Asians. Am J Cardiol 2007, 99:410-414.
14. Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13.
15. Furukawa T.A., Barbui C., Cipriani A., Brambilla P., Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 2006, 59:7-10.
16. Fletcher J. What is heterogeneity and is it important?. Brit Med J 2007, 334:94-96.
17. Hsuan C.F., Lee T.L., Chang H.L., Tseng W.K., Wu C.C. A retrospective study of statin use and its effectiveness in Taiwanese. Acta Cardiol Sin 2009, 25:18-25.
18. Barakat L., Jayyousi A., Bener A., Zuby B., Zirie M. Comparison of efficacy and safety of rosuvastatin, atorvastatin and pravastatin among dyslipidemic diabetic patients. ISRN Pharmacol 2013, 2013:146579.
19. Maruyama T., Takada M., Nishibori Y., Fujita K., Miki K., Masuda S., et al. Comparison of preventive effect on cardiovascular events with different statins -- the CIRCLE study. Circ J 2011, 75:1951-1959.
20. Fox K.M., Gandhi S.K., Ohsfeldt R.L., Blasetto J.W., Bays H.E. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Curr Med Res Opin 2007, 23:2125-2133.
21. Matsuzawa Y., Kita T., Mabuchi H., Matsuzaki M., Nakaya N., Oikawa S., et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003, 67:287-294. J.L.S. Group.
22. U.S.Food and Drug Administration Center for drug evaluation and research FDA Public Health Advisory on Crestor (Rosuvastatin) 2005 March 2.
23. Karlson B.W., Barter P.J., Palmer M.K., Lundman P., Nicholls S.J. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. Nutr Metab Cardiovasc Dis 2012, 22:697-703.
24. Sviridov D., Nestel P.J. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 2007, 18:157-163.
25. Kolovou G., Mihas C., Anagnostopoulou K., Kolovou V., Giannakopoulou V., Kostakou P., et al. Cholesteryl ester transfer protein gene and effectiveness of lipid lowering of atorvastatin. Open Cardiovasc Med J 2010, 4:297-301.
26. Huang Y., Wu Y., Liu R., Fan P., Zhang J., Wang F., et al. Differential effect of ATP binding cassette transporter A1 R219K and cholesteryl ester transfer protein TaqIB genotypes on HDL-C levels in overweight/obese and non-obese Chinese subjects. Acta Cardiol 2011, 66:231-237.
27. Pan S.L., Wang F., Lu Z.P., Liu C.W., Hu C.Y., Luo H., et al. Cholesteryl ester transfer protein TaqIB polymorphism and its association with serum lipid levels and longevity in Chinese Bama Zhuang population. Lipids Health Dis 2012, 11:26.
28. Maejima T., Yamazaki H., Aoki T., Tamaki T., Sato F., Kitahara M., et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004, 324:835-839.
29. Yamashita S., Tsubakio-Yamamoto K., Ohama T., Nakagawa-Toyama Y., Nishida M. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb 2010, 17:436-451.
30. Barter P.J., Brandrup-Wognsen G., Palmer M.K., Nicholls S.J. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 2010, 51:1546-1553.